UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM 8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of report
(Date of earliest event reported): May 31, 2016
Phibro
Animal Health Corporation
(EXACT NAME
OF REGISTRANT AS SPECIFIED IN CHARTER)
| Delaware |
01-36410 |
13-1840497 |
(State
or other jurisdiction of
incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
Glenpointe Centre East, 3rd Floor
300 Frank W. Burr Boulevard, Suite 21
Teaneck, New Jersey 07666-6712
(Address
of Principal Executive Offices, including Zip Code)
(201) 329-7300
(Registrant’s
telephone number, including area code)
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below if this
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION
OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
(b) On
May 31, 2016, Gerald K. Carlson, a member of the Board of Directors (the “Board”) of Phibro Animal Health Corporation
(the “Company”) and the Company’s Chief Operating Officer, informed the Company that he is retiring from his
position as Chief Operating Officer effective July 1, 2016. Mr. Carlson has not resigned from his position on the Board of the
Company and plans to serve the remainder of his term as a director. Following his retirement, Mr. Carlson will receive the same
compensation as other non-employee directors receive for their service on the Board. We expect that Mr. Carlson and the Company
will also enter into the Company’s standard director indemnification agreement following his retirement, which will require
the Company to indemnify Mr. Carlson to the fullest extent permitted under Delaware law against liabilities that may arise by reason
of his service on the Board and to advance expenses incurred as a result of any proceeding against him for which he could be indemnified.
Mr. Carlson’s retirement is solely for personal reasons and is not due to any disagreement with the Company, the Company’s
management or the Board.
(c) On
May 31, 2016, the Company also announced the appointment of Larry L. Miller as the Chief Operating Officer of the Company, effective
July 1, 2016, to fill the vacancy left by the retirement of Mr. Carlson.
Mr. Miller is 52 years old and currently
serves as President, Animal Health of the Company. Mr. Miller joined the Company in that role in May 2008. Prior to joining the
Company, Mr. Miller was, from 2004 to 2008, Vice President of the Global Ruminant Business with Intervet/Schering-Plough Animal
Health, which at that time was the largest animal health ruminant business in the world. From 1998 to 2004, Mr. Miller was General
Manager for Schering-Plough’s Australia and New Zealand Animal Health businesses, which included a diversified portfolio
of animal health and nutrition products for beef and dairy cattle, sheep, swine, poultry and companion animals. Mr. Miller held
numerous roles in sales and marketing management during his 17 years with Schering-Plough, and prior to that with American Cyanamid
Animal Health and Nutrition. He holds a B.S. degree in Animal Science from the University of Nebraska and an Executive MBA degree
from the City University of New York. Mr. Miller is a member of the Board of Trustees of the University of Nebraska Foundation
and a member of the Board of Directors of the Nebraska Innovation Campus Development Corporation of the University of Nebraska-Lincoln.
Mr. Miller’s employment agreement
has not been amended.
(e) On
May 31, 2016, the Company and Mr. Carlson entered into an amendment (the “Amendment”) to the Employment Agreement dated
March 27, 2014 between the Company and Mr. Carlson (the “Employment Agreement”). Pursuant to the Amendment, Mr. Carlson
and his spouse will waive their right to participate in the Company’s Retirement Health Care Plan upon his retirement in
exchange for a lump sum cash payment of $350,000, payable following the receipt by the Company of releases from Mr. Carlson and
his spouse. The Amendment also provides that Mr. Carlson will be entitled to a lump sum payment, payable following the receipt
by the Company of a release from Mr. Carlson, of one-third of his base salary in the event his employment with the Company is terminated
by the Company without Cause (as such term is defined in the Employment Agreement) or by Mr. Carlson for any reason, in either
case prior to December 31, 2016. This payment is in addition to certain other payments described in the Employment Agreement which
are payable to Mr. Carlson in the event his employment with the Company is terminated without Cause by the Company or by Mr. Carlson
for any reason.
ITEM 7.01 REGULATION FD DISCLOSURE
On May 31, 2016, the Company issued a press
release announcing the retirement of Mr. Carlson and the appointment of Mr. Miller as Chief Operating Officer. A copy of the press
release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in this press
release is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of, or otherwise regarded
as filed under, the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated
by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such filing.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
Exhibit
Number |
|
Description |
| |
|
|
| 99.1 |
|
Press Release, dated May 31, 2016. |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
| |
PHIBRO ANIMAL HEALTH CORPORATION
Registrant |
| |
|
|
| Date: May 31, 2016 |
|
|
| |
|
|
| |
By: |
/s/ Thomas G. Dagger |
| |
Name: |
Thomas G. Dagger |
| |
Title: |
Senior Vice President, General Counsel |
| |
|
and Corporate Secretary |
